Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.1 , No. 1, Publication Date: Jul. 7, 2014, Page: 26-30
![](https://www.facebook.com/dialog/feed?app_id=808315475849687&link=http://www.aascit.org/journal/archive2?journalId=906%26paperId=371&redirect_uri=http://www.aascit.org/journal/archive2?journalId=906%26paperId=371&display=popup&name=Clinical Characteristics and Therapeutic Outcome of Patients with Febrile Neutropenia: Our Clinical Experience&description=Aim: The aim of this paper is to present our experience in the treatment of adult patients with malignant disease: breast cancer, digestive cancer, gynecological cancer, urological cancer and malignant disease of the lungs. Introduction: Neutropenia exists when there is an absolute decrease in the number of circulating neutrophils, less than 1.0 x10/9/l. Febrile neutropenia exists when a patient with a neutrophil count less than 1.0 x10/9/l has a temperature greater than or equal to 38,0 C. Patients and methods: From January 2000 to December 2013 in the oncology department of the General Hospital "Sveti returns" in Bijeljina were analyzed in 1594 patients with malignancies who are commonly treated in our hospital.We analyzed 270 (16,9%) patients with febrile neutropenia. Results: Most patients had received chemotherapy for breast carcinoma of 75, 66 of the patients had digestive carcinoma, 51 had a gynecological carcinoma, urological carcinoma had 36 and 42 patients had pulmonary carcinomas. Cultures were positive in only 36 patients (13,3%). Most were isolated: Staphylococcus epidermidis in 12 patients, Staphylococcus aureus in 5, Enterococcus faecalis in 5, E. coli in 3, Acinetobacter 2, Serratia spp. 2, Pseudomonas aeruginosa in 3, and Candida albicans in 4 patients. Three patients died due to sepsis. Conclusion: Febrile Neutropenia is a medical emergency and has a significant impact on morbidity and mortality. Treating febrile neutropenia is associated with high healthcare costs. Management of febrile neutropenia requires continuous monitoring and the prompt removal of the source of infection.&picture=http://www.aascit.org/aascit/decorators/img/journal/906.jpg)
| [1] | Sinisa Maksimovic , Public hospital "St Vracevi" in Bijeljina, Bosnia and Herzegovina, Filipa Visnjica St. 22/7, 76300 Bijeljina. |
Aim: The aim of this paper is to present our experience in the treatment of adult patients with malignant disease: breast cancer, digestive cancer, gynecological cancer, urological cancer and malignant disease of the lungs. Introduction: Neutropenia exists when there is an absolute decrease in the number of circulating neutrophils, less than 1.0 x10/9/l. Febrile neutropenia exists when a patient with a neutrophil count less than 1.0 x10/9/l has a temperature greater than or equal to 38,0 C. Patients and methods: From January 2000 to December 2013 in the oncology department of the General Hospital "Sveti returns" in Bijeljina were analyzed in 1594 patients with malignancies who are commonly treated in our hospital.We analyzed 270 (16,9%) patients with febrile neutropenia. Results: Most patients had received chemotherapy for breast carcinoma of 75, 66 of the patients had digestive carcinoma, 51 had a gynecological carcinoma, urological carcinoma had 36 and 42 patients had pulmonary carcinomas. Cultures were positive in only 36 patients (13,3%). Most were isolated: Staphylococcus epidermidis in 12 patients, Staphylococcus aureus in 5, Enterococcus faecalis in 5, E. coli in 3, Acinetobacter 2, Serratia spp. 2, Pseudomonas aeruginosa in 3, and Candida albicans in 4 patients. Three patients died due to sepsis. Conclusion: Febrile Neutropenia is a medical emergency and has a significant impact on morbidity and mortality. Treating febrile neutropenia is associated with high healthcare costs. Management of febrile neutropenia requires continuous monitoring and the prompt removal of the source of infection.
Keywords
Febrile Neutropenia, Malignancy, Complication
Reference
| [01] | Meidani M, Khorvash F, Abolghasemi H, Jamali B. Procalcitonin and quantitative C-reactive protein role in the early diagnosis of sepsis in patients with febrile neutropenia. South Asian J Cancer. 2013;2(4):216-9 |
| [02] | Ahmadzadeh A, Varnasseri M, Jalili MH, Maniavi F, Valizadeh A, Mahmoodian M, Keyhani M. Infection Pattern of Neutropenic Patients in Post-chemotherapy Phase of Acute Leukemia Treatment. Hematol Rep.2013;4(4):4-9. |
| [03] | Meidani M, Khorvash F, Abolghasemi H, Jamali B. Procalcitonin and quantitative C-reactive protein role in the early diagnosis of sepsis in patients with febrile neutropenia. South Asian J Cancer. 2013;2(4):216-9 |
| [04] | Douglas D. Antifungals cut risk of invasive infections in neutropenic patients. Reuters Health Information[serial online]. September 9, 2013;Accessed September 17, 2013.. |
| [05] | Ferdosian F, Ghiliyan R, Hashemi A, Akhondzadeh B, Gholampoor E. Comparing the efficacy of ceftazidime and meropenem in treatment of febrile neutropenia in pediatric patients with cancer., Iran J Ped Hematol Oncol. 2013;3(3):103-7. |
| [06] | Legrand M, Max A, Peigne V, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med. 2012; 40(8):43-47. |
| [07] | El Helou G, Hachem R, Viola GM, et al. Management of rapidly growing mycobacterial bacteremia in cancer patients. Clin Infect Dis.2013;56(7):837-43. |
| [08] | Wingard JR, Eldjerou L, Leather H. Use of antibacterial prophylaxis in patients with chemotherapy-induced neutropenia. Curr Opin Hematol.2012;19(2):16-21. |
| [09] | Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis.2011; 24(3):545-50. |
| [10] | McKenzie H, Hayes L, White K, et al. Chemotherapy outpatients' unplanned presentations to hospital: a retrospective study. Support Care Cancer.2011; 19(5): 957-63. |
| [11] | Lopez-Posa A., Rifa J., Casas De Tejerina A., et al. Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours, European Journal of Cancer Care.2010;19(6):1-10. |
| [12] | Aapro MS, Cameron DA, Pettengell R, et al., European Organization for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer.2006;42:2433–2453. |
| [13] | D Cameron, Management of chemotherapy-associated febrile neutropenia, British Journal of Cancer.2009;101,S18–S22. |
| [14] | Y. Nakagawa, K. Suzuki, T. Masaoka, Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy.J Infect Chemother. 2009;15:174–179. |
| [15] | Palazzi DL. The Use of Antimicrobial Agents in Children with Fever During Chemotherapy-induced Neutropenia. Pediatric Infectious Disease Journal. October,2011;30(0),887-890 |
| [16] | Hebart H, Klingspor L, Klingebiel T, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. Bone Marrow Transplant.2009;43:553–61. |
| [17] | de Pauw BE, Donnelly JP. Timely intervention for invasive fungal disease: should the road now lead to the laboratory instead of the pharmacy? Clin Infect Dis.2009;48:1052–4. |
| [18] | National Cancer Center Network (NCCN). Myeloid growth factors: NCCN practice guidelines. 009: v.1.2009. |
| [19] | Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol.2010;28:2481–90. |
